Silverfin false false 31/03/2024 01/04/2023 31/03/2024 Dr David Lars Sanders 21/03/2022 09 October 2024 The principle activity of the company during the financial period was the design and development of specialist medical products. 13990771 2024-03-31 13990771 bus:Director1 2024-03-31 13990771 2023-03-31 13990771 core:CurrentFinancialInstruments 2024-03-31 13990771 core:CurrentFinancialInstruments 2023-03-31 13990771 core:ShareCapital 2024-03-31 13990771 core:ShareCapital 2023-03-31 13990771 core:RetainedEarningsAccumulatedLosses 2024-03-31 13990771 core:RetainedEarningsAccumulatedLosses 2023-03-31 13990771 2023-04-01 2024-03-31 13990771 bus:FilletedAccounts 2023-04-01 2024-03-31 13990771 bus:SmallEntities 2023-04-01 2024-03-31 13990771 bus:AuditExemptWithAccountantsReport 2023-04-01 2024-03-31 13990771 bus:PrivateLimitedCompanyLtd 2023-04-01 2024-03-31 13990771 bus:Director1 2023-04-01 2024-03-31 13990771 2022-03-21 2023-03-31 iso4217:GBP xbrli:pure

Company No: 13990771 (England and Wales)

CREATE SURGICAL LTD

Unaudited Financial Statements
For the financial year ended 31 March 2024
Pages for filing with the registrar

CREATE SURGICAL LTD

Unaudited Financial Statements

For the financial year ended 31 March 2024

Contents

CREATE SURGICAL LTD

BALANCE SHEET

As at 31 March 2024
CREATE SURGICAL LTD

BALANCE SHEET (continued)

As at 31 March 2024
31.03.2024 31.03.2023
£ £
Current assets
Cash at bank and in hand 687 1,747
687 1,747
Creditors: amounts falling due within one year 3 ( 35,358) ( 29,349)
Net current liabilities (34,671) (27,602)
Total assets less current liabilities (34,671) (27,602)
Accruals and deferred income ( 1,380) ( 1,320)
Net liabilities ( 36,051) ( 28,922)
Capital and reserves
Called-up share capital 1 1
Profit and loss account ( 36,052 ) ( 28,923 )
Total shareholder's deficit ( 36,051) ( 28,922)

For the financial year ending 31 March 2024 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The financial statements of Create Surgical Ltd (registered number: 13990771) were approved and authorised for issue by the Director on 09 October 2024. They were signed on its behalf by:

Dr David Lars Sanders
Director
CREATE SURGICAL LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
CREATE SURGICAL LTD

NOTES TO THE FINANCIAL STATEMENTS

For the financial year ended 31 March 2024
1. Accounting policies

The principal accounting policies are summarised below. They have all been applied consistently throughout the financial year and to the preceding financial period, unless otherwise stated.

General information and basis of accounting

Create Surgical Ltd (the Company) is a private company, limited by shares, incorporated in the United Kingdom under the Companies Act 2006 and is registered in England and Wales. The address of the Company's registered office is 71-75 Shelton Street, Covent Garden, London, WC2H 9JQ, United Kingdom.

The financial statements have been prepared under the historical cost convention, modified to include certain items at fair value, and in accordance with Section 1A of Financial Reporting Standard 102 (FRS 102) ‘The Financial Reporting Standard applicable in the UK and Republic of Ireland’ issued by the Financial Reporting Council and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime.

The financial statements are presented in pounds sterling which is the functional currency of the Company and rounded to the nearest £.

Going concern

The director has assessed the Balance Sheet and likely future cash flows at the date of approving these financial statements. The director has a reasonable expectation that the Company has adequate resources to continue in operational existence and to meet its financial obligations as they fall due for at least 12 months from the date of signing these financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in creditors: amounts falling due within one year.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Ordinary share capital

The ordinary share capital of the Company is presented as equity.

2. Employees

Year ended
31.03.2024
Period from
21.03.2022 to
31.03.2023
Number Number
Monthly average number of persons employed by the Company during the year, including the director 1 1

3. Creditors: amounts falling due within one year

31.03.2024 31.03.2023
£ £
Amounts owed to director 35,358 29,349